Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	36.61B -5.2%
Revenue (ttm)	7.07B +8.7%
Net Income	771.46M +129.9%
EPS	0.92 +135.5%
Shares Out	855.14M
PE Ratio	49.20
Forward PE	34.79
Dividend	0.13 (0.28%)
Ex-Dividend Date	Jun 17, 2025

Volume	40,248,235
Open	45.07
Previous Close	45.05
Day's Range	43.58 - 50.10
52-Week Range	35.57 - 71.90
Beta	0.43
Analysts	Buy
Price Target	63.81 (+29.8%)
Earnings Date	Aug 28, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Analyst Summary

According to 17 analysts, the average rating for 300347 stock is "Buy." The 12-month stock price target is ¥63.81, which is an increase of 29.80% from the latest price.

Price Target

¥63.81

(29.80% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 29, 2026

Data Sources Report a data error